News
Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...
Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...
16h
InvestorsHub on MSNNovo Nordisk Shares Climb for Second Day as Lilly’s Obesity Pill Falls Short of Wegovy in Trial
Shares of Novo Nordisk (NYSE:NVO), traded in Copenhagen, rose over 5% on Friday, extending gains from the previous session.
Lilly executives have touted the once-daily pill, known as orforglipron, as a cheaper alternative to recently-popular obesity injections like its Zepbound offering or Novo’s Wegovy. Both of the ...
A man who says he got 'Ozempic penis' from the weight loss drug Wegovy has opened up on how his sex life has been going ...
Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...
Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...
Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...
17h
The National on MSNDaily pill helps patients lose 12 per cent of body weight in clinical tests
A trial of 3,127 patients who took a daily pill for 72 weeks saw an average weight loss per person of 12.3kg. While injectable obesity drugs are peptides designed to replicate the appetite-controlling ...
Under Armour (NYSE: UA) stock slumped 13% after the athletic apparel maker forecast second-quarter revenue below expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results